RESULTS OF CLINICAL STUDY OF RUSSIAN BIOANALOGUE FOR INTERFERON-BETA-1b
Еkaterina Vadimovna Baidina , Аlexei Nikolaevich Boyko , Vasily Valerjevich Brukhov , Еvgeny Ivanovich Gusev , Lubov Vladimirovna Dubchak , Igor Alexeevich Zavalishin , Roman Аlexeevich Ivanov , Sergei Vikyorovich Коtov , Маrina Viktorovna Кrotenkova , Veronica Igorevna Par , Таtyana Еvgenievna Shmidt , Sergei Gennadievich Schur , Nikolai Nikolaevich Jahno
Neurology Bulletin ›› 2010, Vol. XLII ›› Issue (1) : 41 -48.
RESULTS OF CLINICAL STUDY OF RUSSIAN BIOANALOGUE FOR INTERFERON-BETA-1b
There were presented results of many-sided perspective randomized comparative clinical study of Russian preparation Interferon-Beta-1b - ronbetal and of original preparation Betaferon. During 7,5 months of taking of these preparations there was conducted a monthly magnetic resonance tomography together with intravenous injection of paramagnetic contrast agent. This clinical investigation has demonstrated equal safety, tolerance and effectiveness of Ronbetal and Interferon.
multiple sclerosis / Interferon Beta-1b / therapy by Interferon / Ronbetal / bioanalogue / randomized many-sided clinical study
| [1] |
1. Гусев, Е.И. Современные подходы к использованию бета-интерферонов в лечении рассеянного склероза / Е.И. Гусев, А.Н. Бойко // Журн. неврол. и психиатр. - 2000, -№11. - С. 54-59. |
| [2] |
2. Новик, А.А. Исследование качества жизни в медицине [под ред. Ю.Л. Шевченко] / А.А. Новик, Т.И. Ионова. - М.: ГЭОТАР-МЕД, 2004. - 304 с. |
| [3] |
3. Bayas, A. Managing the Adverse Effects of Interferon-в Therapy in Multiple Sclerosis / A. Bayas, P. Reickmann // Drug. Safety. - 2000. - Vol. 22. - P. 149-159. |
| [4] |
4. Durelli, L. Every-one-day interferon-beta-1b versus once-weekly interferon-beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN) / L. Durelli, E. Verdun, P. Barbero et al. // Lancet. - 2002. - Vol. 27. - P. 1453-1460. |
| [5] |
5. ЕМЕА. The rules governing medicinal products in the European Union. Investigation of Bioavailability and Bioequivalence. - 1998. - Vol. 3C. - P. 231-244. |
| [6] |
6. European Study Group on Interferon-b-1b in Secondary Progressive MA. Placebo-controlled multicentre randomised trial of interferon-b-1b in treatment of secondary progressive multiple sclerosis (by Ludwig Kappos) // Lancet. - 1998. - Vol. 352. - P. 1491-1497. |
| [7] |
7. Gaines, A.R. Interferon beta-1b injection site reactions and necrosis / A.R .Gaines, F. Varrichio// Multiple Sclerosis. - 1998. - Vol. 4. - P. 70-73. |
| [8] |
8. Goodkin, D.E. CA and the North American Study Group on Interferon-beta-1b in Secondary Progressive MS. Interferon-beta-1b in Secondary Progressive MS: clinical and MRI results of a 3-year randomized controlled trial [abstract no.LBN.004]. /52th Annual Meeting of the American Academy of Neurology Late Breakers; 2000 Apr 29 - May 6, San Diego, USA. режим доступа: http//www.fda.gov/cder/biologics/review/ifnbchi 031403r2.pdf. |
| [9] |
9. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS; final outcome of the randomized controlled trial // Neurology. - 1995. - Vol. 45. - P. 1277-1285. |
| [10] |
10. IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial // Neurology. - 1993. - Vol. 43. - P. 655-661. |
| [11] |
11. Lublin, F.D. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference / F.D. Lublin, J.N. Whitaker, B.H. Eidelman et al. // Neurology. - 1996. - Vol. 46. - P. 12-18. |
| [12] |
12. Lyseng-Williamson, KA. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis / K.A. Lyseng-Williamson, D. Murdoch // Drugs. - 2005. - Vol. 65(9). - P. 1295-312. |
| [13] |
13. Miller, D.H. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis / D.H. Miller, P.D. Molyneux, G.J. Barker et al. // Ann. Neurol. - 1999 Dec. - Vol. 46(6). - P. 850-859. |
| [14] |
14. Mohr, D.C. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment / D.C. Mohr, D.E. Goodkin, W. Likosky et al. // Multiple Sclerosis. - 1996. - Vol. 2. - P. 222-226. |
| [15] |
15. Munschauer, F.E. Managing side effects of Interferon-beta in patients with relapsing-remitting multiple sclerosis / F.E. Munschauer, R.P. Kinkel // Clin. Therap.- 1997. - Vol. 19. - P. 883-893. |
| [16] |
16. Paty, D.W. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines / D.W. Paty, H.P. Hartung, G.C. Ebers et al. // Eur J. Neurol. - 1999. - Vol. 6 (Suppi 1). - P. 1-35. |
| [17] |
17. Paty, D.W. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. The UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group / D.W. Paty, D.K. Li // Neurology. - 1993. - Vol. 43. - P. 662-667. |
| [18] |
18. Rice, G.P. et al. Ibuprofen treatment versus gradual introduction of interferon в-1b in patient with MS // Neurology. - 1999. - Vol. 52(9). - P. 1893-1895. |
| [19] |
19. Rudick, R.A. Treatment of multiple sclerosis with type I interferons. / R.A. Rudick, W. Sibley, L. Durelli / In: Multiple sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives. - Springer-Verlag, London, 1996. - P. 230-231. |
| [20] |
20. Walther, E.U. Managment of side effects of beta-interferon therapy in MS / E.U. Walther, T. Dang, R. Hohlfeld // Int. MS J. - 1999. - Vol. 5. - P. 65-70. |
| [21] |
21. Walther, E.U. Multiple sclerosis. Side effects of interferon beta therapy and their management / E.U. Walther, R. Hohlfeld // Neurology. - 1999. - Vol. 53. - P. 1622-1633. |
Baidina Е.V., Boyko А.N., Brukhov V.V., Gusev Е.I., Dubchak L.V., Zavalishin I.A., Ivanov R.А., Коtov S.V., Кrotenkova М.V., Par V.I., Shmidt Т.Е., Schur S.G., Jahno N.N.
/
| 〈 |
|
〉 |
PDF
